Serum KL-6 as a biomarker to predict progression at one year in interstitial lung disease

About one third of non-IPF ILD patients progresses over time. Serum KL-6, a lung epithelial mucin type 1, is an established marker to assess disease severity in ILD but its ability to predict progression needs to be further explored. To investigate whether serum KL-6 is of additional value to strati...

ver descrição completa

Detalhes bibliográficos
Autores: Bonella, Francesco, Vegas Sánchez, M.C., Alessandro, M. d', Millan Billi, P., Santos, R.F., Schröder, N., Bastos, H. N., Molina Molina, M., Sánchez Pernaute, O., Castillo Villegas, D., Bargagli, E.
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2025
País:España
Recursos:Universidad de Oviedo (UNIOVI)
Repositório:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/224335
Acesso em linha:https://hdl.handle.net/2445/224335
Access Level:Acceso aberto
Palavra-chave:Diagnòstic immunohistoquímic
Marcadors tumorals
Fibrosi pulmonar
Diagnostic immunohistochemistry
Tumor markers
Pulmonary fibrosis
id ES_4cd0cbcc47463ee5e01b36da60ee4444
oai_identifier_str oai:diposit.ub.edu:2445/224335
network_acronym_str ES
network_name_str España
repository_id_str
spelling Serum KL-6 as a biomarker to predict progression at one year in interstitial lung diseaseBonella, FrancescoVegas Sánchez, M.C.Alessandro, M. d'Millan Billi, P.Santos, R.F. Schröder, N.Bastos, H. N. Molina Molina, M.Sánchez Pernaute, O.Castillo Villegas, D.Bargagli, E.Diagnòstic immunohistoquímicMarcadors tumoralsFibrosi pulmonarDiagnostic immunohistochemistryTumor markersPulmonary fibrosisAbout one third of non-IPF ILD patients progresses over time. Serum KL-6, a lung epithelial mucin type 1, is an established marker to assess disease severity in ILD but its ability to predict progression needs to be further explored. To investigate whether serum KL-6 is of additional value to stratify the patients for the risk of developing clinical or functional progression at one year. ILD patients from 6 European centers were retrospectively enrolled. Disease progression was defined as relative decline >= 10% in FVC or >= 15% in DLco from baseline. Serum KL-6 was measured using a full-automated chemiluminescent immunoassay (Fujirebio). Comparative logistic regression was used to identify predictors of progression at one year. 303 patients were included. 37% developed progression after one year from KL-6 measurement. A stepwise selection was used to identify and include five predictors of progression in a risk score: age, gender, BMI, FVC, and KL-6. The final model was superior to KL-6 alone to predict progression at one year, with 55% sensitivity, 73% specificity and 67% accuracy at a cut-off of 5. Patients were stratified in low and high risk of progression at one year based on the cut-off of 5, with a similar accuracy for IIP 0.687 and CTD-ILD 0.720 but not for HP. Serum KL-6 levels, included in a risk score with other clinical and functional variables, may help to better stratify patients for the risk of disease progression at one year, compared to any individual predictor.Springer Science and Business Media LLC2025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/224335Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Dipòsit Digital de la UBinstname:Universidad de Oviedo (UNIOVI)InglésReproducció del document publicat a: https://doi.org/10.1038/s41598-025-22483-4Scientific Reports, 2025, vol. 15, 35243https://doi.org/10.1038/s41598-025-22483-4cc-by (c) Bonella, Francesco et al., 2025https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/2243352026-05-27T06:46:51Z
dc.title.none.fl_str_mv Serum KL-6 as a biomarker to predict progression at one year in interstitial lung disease
title Serum KL-6 as a biomarker to predict progression at one year in interstitial lung disease
spellingShingle Serum KL-6 as a biomarker to predict progression at one year in interstitial lung disease
Bonella, Francesco
Diagnòstic immunohistoquímic
Marcadors tumorals
Fibrosi pulmonar
Diagnostic immunohistochemistry
Tumor markers
Pulmonary fibrosis
title_short Serum KL-6 as a biomarker to predict progression at one year in interstitial lung disease
title_full Serum KL-6 as a biomarker to predict progression at one year in interstitial lung disease
title_fullStr Serum KL-6 as a biomarker to predict progression at one year in interstitial lung disease
title_full_unstemmed Serum KL-6 as a biomarker to predict progression at one year in interstitial lung disease
title_sort Serum KL-6 as a biomarker to predict progression at one year in interstitial lung disease
dc.creator.none.fl_str_mv Bonella, Francesco
Vegas Sánchez, M.C.
Alessandro, M. d'
Millan Billi, P.
Santos, R.F.
Schröder, N.
Bastos, H. N.
Molina Molina, M.
Sánchez Pernaute, O.
Castillo Villegas, D.
Bargagli, E.
author Bonella, Francesco
author_facet Bonella, Francesco
Vegas Sánchez, M.C.
Alessandro, M. d'
Millan Billi, P.
Santos, R.F.
Schröder, N.
Bastos, H. N.
Molina Molina, M.
Sánchez Pernaute, O.
Castillo Villegas, D.
Bargagli, E.
author_role author
author2 Vegas Sánchez, M.C.
Alessandro, M. d'
Millan Billi, P.
Santos, R.F.
Schröder, N.
Bastos, H. N.
Molina Molina, M.
Sánchez Pernaute, O.
Castillo Villegas, D.
Bargagli, E.
author2_role author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Diagnòstic immunohistoquímic
Marcadors tumorals
Fibrosi pulmonar
Diagnostic immunohistochemistry
Tumor markers
Pulmonary fibrosis
topic Diagnòstic immunohistoquímic
Marcadors tumorals
Fibrosi pulmonar
Diagnostic immunohistochemistry
Tumor markers
Pulmonary fibrosis
description About one third of non-IPF ILD patients progresses over time. Serum KL-6, a lung epithelial mucin type 1, is an established marker to assess disease severity in ILD but its ability to predict progression needs to be further explored. To investigate whether serum KL-6 is of additional value to stratify the patients for the risk of developing clinical or functional progression at one year. ILD patients from 6 European centers were retrospectively enrolled. Disease progression was defined as relative decline >= 10% in FVC or >= 15% in DLco from baseline. Serum KL-6 was measured using a full-automated chemiluminescent immunoassay (Fujirebio). Comparative logistic regression was used to identify predictors of progression at one year. 303 patients were included. 37% developed progression after one year from KL-6 measurement. A stepwise selection was used to identify and include five predictors of progression in a risk score: age, gender, BMI, FVC, and KL-6. The final model was superior to KL-6 alone to predict progression at one year, with 55% sensitivity, 73% specificity and 67% accuracy at a cut-off of 5. Patients were stratified in low and high risk of progression at one year based on the cut-off of 5, with a similar accuracy for IIP 0.687 and CTD-ILD 0.720 but not for HP. Serum KL-6 levels, included in a risk score with other clinical and functional variables, may help to better stratify patients for the risk of disease progression at one year, compared to any individual predictor.
publishDate 2025
dc.date.none.fl_str_mv 2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/224335
url https://hdl.handle.net/2445/224335
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1038/s41598-025-22483-4
Scientific Reports, 2025, vol. 15, 35243
https://doi.org/10.1038/s41598-025-22483-4
dc.rights.none.fl_str_mv cc-by (c) Bonella, Francesco et al., 2025
https://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) Bonella, Francesco et al., 2025
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springer Science and Business Media LLC
publisher.none.fl_str_mv Springer Science and Business Media LLC
dc.source.none.fl_str_mv Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
reponame:Dipòsit Digital de la UB
instname:Universidad de Oviedo (UNIOVI)
instname_str Universidad de Oviedo (UNIOVI)
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407651553607680
score 15,811543

Registros relacionados